GSK has received a £4 million award from the Trust to accelerate development of compounds for the treatment of Gram-negative bacteria which are becoming increasingly resistant to multiple antibacterials. GSK will make a matching contribution in staff, equipment, and other programme costs. The Trust will receive a financial consideration on any commercial product resulting from the collaboration.
"Our ability to tackle drug-resistant infections is reaching crisis level with few new antimicrobial agents on the horizon," says Dr Ted Bianco, Director of Technology Transfer at the Wellcome Trust. "Antibacterials are expensive to develop and may be held in reserve, limiting their market potential. It can be difficult, therefore, for companies to recoup their outlay in R&D costs.
“This is where the Wellcome Trust believes it can make a difference through partnership. GSK has demonstrated a continuing commitment to discover and develop new antibacterials, aimed at addressing the growing threat of resistance. Our partnership will further support its research programmes."
The research will target Gram-negative bacteria, such as Pseudomonas, Klebsiella and Acinetobacter, which are increasingly resistant to available antibacterials and commonly cause hospital-acquired pneumonia and septic shock, particularly in patients in intensive care units. Without adequate therapy, patients often confront a poor prognosis – mortality is high, and recovery, when it occurs, can be long and complicated.
Dr Patrick Vallance, Senior Vice President of Drug Discovery at GSK, commented: “Infection by Gram-negative bacteria is a rapidly emerging public-health problem. GSK welcomes this collaboration with the Wellcome Trust to evaluate the potential of part of our existing antibiotics portfolio against these pathogens.”
Virtually no novel-mechanism antibacterials are in development to address this rising need. Gram-negative bacteria are particularly difficult to attack as they have an outer membrane surrounding the bacterial cell wall which interferes with drug penetration. New medicines must not only be toxic to the pathogen, but must first overcome the barriers to entry into the cell.
The resistance of various types of bacteria to treatment is creating new challenges in the management of infection. Few new antibiotic classes have entered the market in the last 40 years. In recognition of this challenge, GSK’s Infectious Diseases Centre of Excellence for Drug Discovery (ID CEDD) is dedicated to research into medicines for bacterial as well as other types of infections.
The Wellcome Trust's £91 million Seeding Drug Discovery initiative aims to assist researchers and companies, small and large, to take forward early-stage drug discovery projects in small-molecule therapeutics. It is intended that these projects will then be taken up for further research and development by industry.
"Our partnership with GSK will capitalise on the company's research excellence and support it in developing a much needed product," explains Dr Bianco. “More generally, the public and private sectors must find creative ways to address antibiotic development, or face the spectre of being confronted with untreatable infections”.
The Wellcome Trust is currently accepting applications for the next round of funding under the Seeding Drug Discovery initiative. Preliminary applications submitted by 4 May 2007 will be short-listed for consideration by the committee in October 2007.
Resolving the mystery of preeclampsia
21.10.2016 | Universitätsklinikum Magdeburg
New potential cancer treatment using microwaves to target deep tumors
12.10.2016 | University of Texas at Arlington
Researchers from the Institute for Quantum Computing (IQC) at the University of Waterloo led the development of a new extensible wiring technique capable of controlling superconducting quantum bits, representing a significant step towards to the realization of a scalable quantum computer.
"The quantum socket is a wiring method that uses three-dimensional wires based on spring-loaded pins to address individual qubits," said Jeremy Béjanin, a PhD...
In a paper in Scientific Reports, a research team at Worcester Polytechnic Institute describes a novel light-activated phenomenon that could become the basis for applications as diverse as microscopic robotic grippers and more efficient solar cells.
A research team at Worcester Polytechnic Institute (WPI) has developed a revolutionary, light-activated semiconductor nanocomposite material that can be used...
By forcefully embedding two silicon atoms in a diamond matrix, Sandia researchers have demonstrated for the first time on a single chip all the components needed to create a quantum bridge to link quantum computers together.
"People have already built small quantum computers," says Sandia researcher Ryan Camacho. "Maybe the first useful one won't be a single giant quantum computer...
COMPAMED has become the leading international marketplace for suppliers of medical manufacturing. The trade fair, which takes place every November and is co-located to MEDICA in Dusseldorf, has been steadily growing over the past years and shows that medical technology remains a rapidly growing market.
In 2016, the joint pavilion by the IVAM Microtechnology Network, the Product Market “High-tech for Medical Devices”, will be located in Hall 8a again and will...
'Ferroelectric' materials can switch between different states of electrical polarization in response to an external electric field. This flexibility means they show promise for many applications, for example in electronic devices and computer memory. Current ferroelectric materials are highly valued for their thermal and chemical stability and rapid electro-mechanical responses, but creating a material that is scalable down to the tiny sizes needed for technologies like silicon-based semiconductors (Si-based CMOS) has proven challenging.
Now, Hiroshi Funakubo and co-workers at the Tokyo Institute of Technology, in collaboration with researchers across Japan, have conducted experiments to...
14.10.2016 | Event News
14.10.2016 | Event News
12.10.2016 | Event News
21.10.2016 | Health and Medicine
21.10.2016 | Information Technology
21.10.2016 | Materials Sciences